Repurposing Pyramax for the Treatment of Ebola Virus Disease: Additivity of the Lysosomotropic Pyronaridine and Non-Lysosomotropic Artesunate
T. R. Lane, J. Dyall, L. Mercer, C. Goodin, D. H. Foil, H. Zhou, E. Postnikova, J. Y. Liang, M. Holbrook, P. Madrid, S. Ekins
The paper evaluates the antiviral efficacy of Pyramax(R), a malaria treatment, against Ebola virus and finds its components act additively to inhibit infection.
bioRxiv · Apr 25, 2020 · PreprintPharmacology & Toxicology